㈜셀레믹스

Publications

Celemics’ Publications

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients

  • Post category:Oncology

Cancers

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients

Park JH, Jo JH, Jang SI, Chung MJ, Park JY, Bang S, et al. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Cancers (Basel). 2022 Jan 4;14(1):236.

 

DOI 10.3390/cancers14010236